In recent articles, I have argued for an approach to presbyopia correction that selects a presbyopic IOL according to each patient’s unique presbyopia profile. In my experience, this customized ...

NEW YORK--(BUSINESS WIRE)-- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced ...

The FDA has approved Deseyne contact lenses with extended depth of focus for the correction of presbyopia, according to a ...

A Prescription Drug User Fee Act target date of January 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Brimochol ™ ...

Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in ...

Exclusive distribution agreement includes revenue sharing in addition to upfront and milestone payments to LENZSAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ ...

The US. Food and Drug Administration (FDA) has officially cleared Deseyne contact lenses, developed by Bruno Vision Care, for ...

The US Food and Drug Administration for the first time has approved an eye drop to treat presbyopia, also known as age-related blurry near vision, in adults. Pilocarpine HCl ophthalmic solution 1.25% ...

The global myopia and presbyopia treatment market is witnessing rapid growth, with a market valuation of USD 17.9 billion in 2022. Projections suggest that the market will experience an impressive ...

LENZ Therapeutics (LENZ) announced an exclusive distribution agreement for Lunatus to register and commercialize VIZZ for the ...